

Results of Annual General Meeting

20 November 2023 – Melbourne, Australia: PharmAust Limited (ASX: PAA), today held its Annual General Meeting of Shareholders at the offices of RSM Australia, Level 21, 55 Collins St, Melbourne VIC 3000.

All resolutions that were put were passed by a poll.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary.

This ASX release has been approved for release by Sam Wright on behalf of the Board of Directors.

Enquiries:

Sam Wright
Finance Director
sam@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
www.pharmaust.com



About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical studies in humans and Phase 2 clinical studies in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical studies.

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Adoption of Remuneration Report	Ordinary	69,963,123 81.39%	5,947,162 6.92%	10,051,538 11.69%	890,017	90,687,483 93.85%	5,947,162 6.15%	890,017	Carried
2 Re-election of Director – Dr Roger Aston	Ordinary	95,497,930 83.48%	8,837,947 7.72%	10,075,538 8.80%	1,108,100	116,246,290 92.93%	8,837,947 7.07%	1,108,100	Carried
3 Approval of Additional 10% Capacity	Special	96,687,359 84.56%	7,592,942 6.64%	10,061,538 8.80%	1,177,676	118,721,719 94.97%	6,292,942 5.03%	1,177,676	Carried
4 Approval to issue Securities under Employee Incentive Scheme	Ordinary	68,015,175 78.48%	8,620,633 9.95%	10,025,961 11.57%	9,708,131	88,713,958 91.14%	8,620,633 8.86%	9,708,131	Carried
5 Approval to issue Options to unrelated parties under Option Offer	Ordinary	73,136,670 84.29%	3,579,138 4.12%	10,056,628 11.59%	9,597,464	93,866,120 96.33%	3,579,138 3.67%	9,597,464	Carried
6 Approval to issue Options under Option Offer to Dr Roger Aston	Ordinary	79,793,568 80.51%	9,283,600 9.37%	10,025,961 10.12%	1,816,771	100,492,351 91.54%	9,283,600 8.46%	1,816,771	Carried
7 Approval to issue Options under Option Offer to Robert Bishop	Ordinary	83,510,454 78.86%	12,354,769 11.67%	10,025,961 9.47%	9,628,331	104,209,237 89.40%	12,354,769 10.60%	9,628,331	Carried
8 Approval to issue Options under Option Offer to Neville Bassett	Ordinary	92,647,568 80.30%	12,721,715 11.02%	10,025,961 8.68%	124,271	113,346,351 89.91%	12,721,715 10.09%	124,271	Carried
9 Approval to issue Options under Option Offer to Sam Wright	Ordinary	88,481,514 81.14%	10,548,674 9.67%	10,022,056 9.19%	6,467,271	109,176,392 91.19%	10,548,674 8.81%	6,467,271	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.